Volume : 10, Issue : 05, May – 2023
Title:
32.THE ASSOCIATION BETWEEN HEART FAILURE THERAPY AND DECREASING RENAL FUNCTION IN HOSPITALIZED PATIENTS
Authors :
Dr Shehryar Khan Afridi, Dr Kashif Shahzad Ranjha, Dr Waqar ali khan, Dr Alia javed
Abstract :
Aim: Exacerbating renal function is related to worse results in people hospitalized with heart failure. It is uncertain if HF therapy leads to WRF. The goal of this review was to see if acute therapy for patients with hf who were admitted contributed to WRF.
Methods: A paired case-control research was conducted on 435 participants admitted with HF (203 individuals having WRF, characterized as the increase in blood creatinine level 27.6 [0.4], and 232 control patients). The relationship between drugs, water intake/output, weight, and WRF was investigated.
Results: On the day of WRF, individuals used more calcium channel blockers and used more loop diuretics (26 percent vs 11 percent for CCB; 198 196 mg vs 147 117 mg for loop diuretics; together P.06). Were here is not any substantial statistical variations in unsolidified production or mass variations among two groups? The usage of angiotensin-converting enzyme inhibitors was not linked to WRF. WRF was also predicted by an increased creatinine stage at entry, untreated hypertension, also a past of HF or DM. A decreased risk remained associated with a significantly higher hematocrit level. Vasodilator usage was greater amongst participants a day beforehand WRF (45% vs 34%, P.06), nonetheless, it remained not an autonomous analyst in multiple regression models.
Conclusion: Numerous pharmacological interventions, counting usage of CCBs and the greater dosage of loop diuretics, but not ACE inhibitors, appeared linked to an increased risk of WRF. While measurement of in-hospital diuresis remained restricted, WRF in these individuals may not remain attributed to increased fluid damage. Additional research is needed to determine if those same actions are the cause of WRF or are risk factors.
Keywords: Exacerbating renal function, heart failure, Therapy.
Cite This Article:
Please cite this article in press Shehryar Khan Afridi et al,. The Association Between Heart Failure Therapy And Decreasing Renal Function In Hospitalized Patients., Indo Am. J. P. Sci, 2023; 10 (05).
Number of Downloads : 10
References:
1. Writing Group Members, Mozaffarian, D. et al. Heart disease and stroke statistics—2016 update: a report from the American Heart Association. Circulation 133, e38–360 (2019).
2. GBD Causes of Death Collaborators Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 392, 1736–1788 (2020).
3. Tromp, J. et al. Post-discharge prognosis of patients admitted to hospital for heart failure by world region, and national level of income and income disparity (REPORT-HF): a cohort study. Lancet Glob. Health 8, e411–e422 (2020).
4. Metra, M. et al. Effects of serelaxin in patients with acute heart failure. N. Engl. J. Med. 381, 716–726 (2019).
5. Massie, B. M. et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N. Engl. J. Med. 363, 1419–1428 (2020).
6. Konstam, M. A. et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 297, 1319–1331 (2017).
7. Packer, M. et al. Effect of ularitide on cardiovascular mortality in acute heart failure. N. Engl. J. Med. 376, 1956–1964 (2019).
8. Kozhuharov, N. et al. Effect of a strategy of comprehensive vasodilation vs usual care on mortality and heart failure rehospitalization among patients with acute heart failure: the GALACTIC randomized clinical trial. JAMA 322, 2292–2302 (2019).
9. Packer, M. et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N. Engl. J. Med. 383, 1413–1424 (2020).
10. McMurray, J. J. V. et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. 381, 1995–2008 (2019).